PentixaPharm, a Wurzburg, Germany-based company committed to developing PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, secured €15m in series A financing.
The round was led by ELSA Eckert Life Science Accelerator. The proceeds of the series A financing will enable the company to continue to develop its new treatment for CNS Lymphoma.
Led by CEO Anna Steeger, PentixaPharm is a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to developing PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma – but also for solid tumors like adrenocortical carcinoma and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke can be visualised with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.